Core Viewpoint - The administrative penalties for insider trading involving the actual controller and former financial director of Nanwei Co., Ltd. have been officially issued, highlighting regulatory actions against insider trading practices in the company [1] Summary by Relevant Sections - **Insider Trading Case** - The actual controller and major shareholder of Nanwei Co., Ltd., Li Ping, and former financial director, Xiang Qinhua, received administrative penalties from the Jiangsu Securities Regulatory Bureau for insider trading [1] - **Financial Penalties** - Li Ping avoided losses of approximately 11.77 million yuan through insider trading, resulting in the confiscation of illegal gains of about 11.77 million yuan and a fine of approximately 35.33 million yuan [1] - Xiang Qinhua avoided losses of about 101,700 yuan, leading to the confiscation of illegal gains of 101,700 yuan and a fine of 1.5 million yuan [1] - The total penalties imposed on both individuals amount to approximately 48.71 million yuan [1] - **Regulatory Timeline** - Both Li Ping and Xiang Qinhua received a notice of investigation from the Securities Regulatory Commission on October 23, 2024, due to suspected insider trading [1] - On August 7, 2025, they received a prior notice of administrative punishment from the Jiangsu Securities Regulatory Bureau [1]

Core Viewpoint - The company, Jiangsu Nanwei Medical Co., Ltd., is facing regulatory scrutiny due to insider trading activities involving its actual controller and former financial director, which has led to significant financial penalties but is stated not to affect the company's operations or listing status [2][4]. Group 1: Regulatory Actions - Li Ping, the actual controller and chairman, sold 8.184 million shares of Nanwei Co. during the sensitive period, resulting in a transaction amount of 47.9678 million yuan and an avoidance of losses amounting to 11.7767 million yuan [2]. - Xiang Qinhua, the former financial director, sold 54,000 shares during the same period, with a transaction amount of 340,500 yuan and an avoidance of losses of 101,700 yuan [2]. - The Jiangsu Regulatory Bureau decided to confiscate illegal gains of 11.7767 million yuan from Li Ping and impose a fine of 35.33 million yuan, while Xiang Qinhua will have 101,700 yuan confiscated and face a fine of 1.5 million yuan [2]. Group 2: Company Performance - Nanwei Co. reported a revenue of approximately 447 million yuan for the first three quarters of 2025, reflecting a year-on-year decrease of 1.7% [3]. - The net loss attributable to shareholders for the same period was approximately 24.93 million yuan, with a basic earnings per share loss of 0.086 yuan [3]. - As of November 4, the company's stock price was 6.84 yuan, with a total market capitalization of 2 billion yuan [3]. Group 3: Company Overview - Nanwei Co. specializes in the research, production, and sales of transdermal products, medical adhesive tapes, bandages, sports protection products, first aid kits, and nursing products [3]. - The company has established a strong partnership with Yunnan Baiyao Group, becoming the exclusive supplier of certain products [3].

Core Points - The chairman and former financial director of Nanwei Co., Ltd. were penalized for insider trading, with total fines and confiscated profits exceeding 48.7 million yuan [2][3]. Group 1: Insider Trading Penalties - Li Ping, the actual controller and chairman, sold 8.184 million shares of Nanwei Co., Ltd. during the sensitive period, with a transaction amount of 47.9678 million yuan, avoiding losses of 11.7767 million yuan [5]. - Xiang Qinhua, the former financial director, sold 54,000 shares during the same period, with a transaction amount of 340,500 yuan, avoiding losses of 101,700 yuan [5]. - The Jiangsu Regulatory Bureau decided to confiscate Li Ping's illegal gains of 11.7767 million yuan and impose a fine of 35.33 million yuan, while Xiang Qinhua faced confiscation of 101,700 yuan and a fine of 1.5 million yuan [5]. Group 2: Company Operations and Financial Performance - Nanwei Co., Ltd. primarily engages in the research, production, and sales of transdermal products, medical adhesive tapes, bandages, sports protection products, first aid kits, and nursing products [6]. - As of the end of Q3 2025, the company reported revenue of approximately 447 million yuan, a year-on-year decrease of 1.7%, and a net loss attributable to shareholders of 24.93 million yuan, further widening the loss [8]. - Li Ping, aged 65, is the largest shareholder of Nanwei Co., Ltd., holding 119 million shares, accounting for 41.12% of the total shares [6][7].

《南卫股份关于公司相关人员收到中国证券监督管理委员会《行政处罚决定书》的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年11月4日收盘，南卫股份（603880）报收于6.84元，较前一交易日上涨0.44%，最新总市值为 19.77亿元。该股当日开盘6.83元，最高6.88元，最低6.77元，成交额达4598.71万元，换手率为2.33%。 近日，南卫股份发布公告称，公司控股股东及实际控制人李平、前任财务总监项琴华因涉嫌内幕交易， 分别于2025年11月4日收到中国证监会江苏监管局下发的《行政处罚决定书》。经查，2023年3月1日公 司资金占用问题基本确认，构成内幕信息，敏感期为2023年3月1日至4月28日。李平在敏感期内控制账 户卖出"南卫股份"818.40万股，避损11,776,667.59元；项琴华在敏感期内卖出5.4万股，避损101,675.47 元。二人行为构成内幕交易，证监会决定对李平没收违法所得并罚款35,330,002.77元，对项琴华没收违 法所得并罚款1,500,000.00元。上述处罚不涉 ...

Core Viewpoint - The chairman and former financial director of Nanwei Co., Ltd. have been penalized for insider trading, with total fines and confiscated profits exceeding 48.7 million yuan [2][4]. Group 1: Insider Trading Penalties - On November 4, Nanwei Co., Ltd. announced that its actual controller and chairman, Li Ping, along with former financial director, Xiang Qinhua, received an administrative penalty from the Jiangsu Regulatory Bureau of the China Securities Regulatory Commission for insider trading [4]. - Li Ping sold 8.184 million shares of Nanwei Co., Ltd. during the sensitive period of insider information, with a transaction amount of 47.9678 million yuan, avoiding losses of 11.7767 million yuan [6]. - Xiang Qinhua sold 54,000 shares during the same period, with a transaction amount of 340,500 yuan, avoiding losses of 101,700 yuan [6]. - The penalties include confiscation of illegal gains and fines: Li Ping was fined 35.33 million yuan and had 11.7767 million yuan confiscated, while Xiang Qinhua was fined 1.5 million yuan and had 101,700 yuan confiscated [7]. Group 2: Company Performance and Operations - Nanwei Co., Ltd. primarily engages in the research, production, and sales of transdermal products, medical adhesive tapes, bandages, sports protection products, first aid kits, and nursing products [9]. - As of the end of Q3 2025, the company reported revenue of approximately 447 million yuan, a year-on-year decrease of 1.7%, and a net loss attributable to shareholders of 24.93 million yuan, indicating an expanded loss [10]. - The company stated that the administrative penalties do not involve the company itself and will not affect its daily operations, which are currently normal [7].

证券代码：603880 证券简称：南卫股份 公告编号：2025-024 江苏南方卫材医药股份有限公司 关于公司相关人员收到中国证券监督管理委员会 《行政处罚决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江苏南方卫材医药股份有限公司（以下简称"公司"）控股股东及实际控制人 李平于2024年10月23日收到中国证券监督管理委员会（以下简称"中国证监会"） 下发的《立案告知书》（编号：证监立案字0102024025号），公司前任财务总监项 琴华于同日收到中国证监会下发的《立案告知书》（编号：证监立案字0102024026 号），因涉嫌内幕交易，根据《中华人民共和国证券法》《中华人民共和国行政处 罚法》等法律法规，中国证监会决定对李平和项琴华立案。具体内容详见公司于2024 年10月24日披露的《南卫股份关于控股股东及高级管理人员收到中国证券监督管理 委员会立案告知书的公告》（公告编号：2024-043）。 2025年8月7日，公司前任财务总监项琴华收到中国证券监督管理委员会江苏监 管局下发的《行政处罚事先告知 ...

公募基金方面，本期较上一季未再披露的公募基金共计2个，包括新华中小市值优选混合、西部利得量 化优选一年持有期混合A。 MACD金叉信号形成，这些股涨势不错！ 2025年10月31日，南卫股份（维权）(603880.SH)发布2025年第三季报。截至2025年10月30日，共有1个 机构投资者披露持有南卫股份A股股份，合计持股量达733.05万股，占南卫股份总股本的2.54%。其 中，机构投资者包括苏州蓝盈创业投资合伙企业(有限合伙)，机构投资者合计持股比例达2.54%。相较 于上一季度，机构持股比例合计下跌了0.02个百分点。 ...

Core Viewpoint - Nanwei Co., Ltd. is a well-known enterprise in the medical dressing industry in China, focusing on the research, production, and sales of medical dressing products, with its product quality and technology ranking among the top in the industry [1] Group 1: Business Performance - For Q3 2025, Nanwei's revenue was 447 million yuan, ranking 33rd out of 50 in the industry, significantly lower than the top competitor, Yingke Medical, which reported 7.425 billion yuan [2] - The main business revenue breakdown includes 121 million yuan from adhesive bandages, accounting for 39.59%, and 86.05 million yuan from protective products, accounting for 28.11% [2] - The net profit for the same period was -24.84 million yuan, ranking 47th out of 50, far below the industry average of 183 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Nanwei's debt-to-asset ratio was 73.87%, an increase from 63.01% in the previous year, significantly higher than the industry average of 23.66% [3] - The gross profit margin for Q3 2025 was 10.68%, down from 12.41% in the previous year and well below the industry average of 48.78% [3] Group 3: Executive Compensation - The chairman and general manager, Li Ping, received a salary of 602,100 yuan in 2024, a slight increase from 600,800 yuan in 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 16.70% to 12,000, while the average number of circulating A-shares held per account increased by 20.05% to 24,000 [5]

江苏南方卫材医药股份有限公司 2025 年第三季度报告 证券代码：603880 证券简称：南卫股份 江苏南方卫材医药股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人李平、主管会计工作负责人李平及会计机构负责人（会计主管人员）王亚华保证季度 报告中财务信息的真实、准确、完整。 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 141,229,954.25 | -7.81 ...

Core Viewpoint - Nanwei Co., Ltd. experienced a stock price decline of 2.14% on October 29, 2023, with a current price of 6.41 CNY per share, reflecting a total market capitalization of 1.853 billion CNY [1] Group 1: Stock Performance - Year-to-date, Nanwei's stock price has increased by 47.36%, while it has seen a decline of 0.77% over the last five trading days [1] - In the past 20 days, the stock price has risen by 9.01%, but it has decreased by 5.04% over the last 60 days [1] Group 2: Company Overview - Nanwei Co., Ltd. was established on July 4, 1990, and went public on August 7, 2017, focusing on the research, production, and sales of transdermal products, medical adhesive tapes, bandages, sports protection products, first aid kits, and nursing products [1] - The company's revenue composition includes: 39.59% from adhesive bandages, 28.11% from protective products, 22.54% from adhesive tapes and bandages, 5.01% from dressings, 2.63% from first aid kits, 1.71% from other products, and 0.40% from topical agents [1] Group 3: Financial Performance - For the first half of 2025, Nanwei reported a revenue of 306 million CNY, representing a year-on-year growth of 1.39%, while the net profit attributable to shareholders was -12.97 million CNY, a decrease of 1363.32% compared to the previous year [1] - As of June 30, 2025, the number of shareholders increased by 48.53% to 14,500, with an average of 19,986 circulating shares per person, down by 32.67% [1] Group 4: Dividend and Institutional Holdings - Since its A-share listing, Nanwei has distributed a total of 77.527 million CNY in dividends, with no dividends paid in the last three years [2] - As of June 30, 2025, the top ten circulating shareholders saw the exit of Huaxia CSI 500 Index Enhanced A (007994) from the list [2]